Kornimate/medical-research-clean huggingface dataset:
ophthalmic artery resistance index after peribulbar block in the presence of epinephrine

Conditions: Ophthalmic Artery; Peribulbar Block

Summary: evaluate ophthalmic artery flow by echo-doppler before and after peribulbar block with lidocaine in presence or absence of epinephrine.

there are controversies regarding the ophthalmic artery (oa) flow after peribulbar block with the addition of epinephrine. therefore, we aimed to evaluate oa flow by echo-doppler before and after peribulbar block with lidocaine in presence or absence of epinephrine. fifty-six patients that were eligible for cataract phacoemulsification surgery were selected. patients were divided into two groups: group 1 - peribulbar block with lidocaine and 1/200.000 epinephrine; group 2 - peribulbar block with lidocaine in the absence of epinephrine. the resistance index (ri) of oa was evaluated using echo-doppler before and 10 min after the peribulbar block.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) i, ii or iii physical status classification * cataract surgery exclusion criteria: * glaucoma * diabetic retinopathy * previous eye surgery in the same eye * ocular trauma * allergic to any protocol medication * uncooperative patients or cognitive difficulties * axial eye diameter of less than 21.0 mm or greater than 25.5 mm.

Keywords: ocular flow cataract surgery peribulbar block ocular doppler
healthy lifestyles after stroke - stroke coach

Conditions: Stroke; Apoplexy; Cerebral Stroke; Cerebrovascular Accident; Cerebrovascular Accident, Acute; Cerebrovascular Apoplexy; Cerebrovascular Stroke; CVA; Stroke, Acute; Vascular Accident, Brain

Summary: the purpose of this study is to examine the efficacy of a lifestyle modification telehealth program on health-related behaviours in community-dwelling individuals living with stroke.

participants recruited in this study will be randomly assigned to either the healthy lifestyle training program, or attention control memory training program. individuals in the healthy lifestyle training program will each receive 7 lifestyle coaching telephone-sessions (30-60 minutes) with a trained lifestyle coach over a 6 month period. individuals in the memory training program will each receive 7 memory coaching telephone sessions (30-60 minutes) with a trained memory training coach over a 6 month period. 100 evaluable subjects will be recruited (124 to accommodate for 20% dropout).

Eligibility criteria:
inclusion criteria: * has experienced a stroke in the last 12 months * 50 years of age or older * living in the community with phone access * mild to moderate stroke severity (i.e., modified rankin scale score ranging from 1 to 4) * able to communicate in english exclusion criteria: * stroke of non-vascular origin * actively engaged in formal stroke rehabilitation services * uncontrolled arrhythmias * significant musculoskeletal or other neurological condition * severe aphasia or dysarthria * not medically stable * pain or co-morbidities which would preclude activity * living in long-term residential care * cognitive impairment, dependent in activities of daily living, and no caregiver participation

Keywords: stroke telehealth rehabilitation stroke coach randomized controlled trial lifestyle behaviours secondary prevention chronic disease self-management
tobacco cessation texting intervention for people living with hiv who smoke in vietnam

Conditions: Tobacco Cessation

Summary: the intersection of smoking and hiv/aids poses a serious public health threat in vietnam. vietnam is dealing with these two challenges with parallel rather than integrated plans. using a computer-tailored texting intervention, study investigators seek to promote the use of an underused, available, government-funded resource (the quitline) and nicotine replacement therapy (nrt) that the quitline provides, thus, promoting cessation among plwh.

m2q2-hiv \[mhealth messaging to motivate quitline use and quitting among persons living with hiv (plwh) in vietnam (m2q2-hiv)\] is an adaptation of a current computer-tailored smoking cessation intervention in vietnam. study investigators seek to promote underused government resources for public health (the quitline) and nicotine replacement therapy (nrt) among plwh in a sustainable manner. investigators will test m2q2-hiv by conducting a randomized control trial with 600 plwh smokers in two provinces in northern vietnam (26 clinics; 9,877 hiv patients). in aim 1, study investigators will conduct formative work to prepare the m2q2-hiv system for plwh smokers. in aim 2, the study team will randomize and follow smokers for six months. the study's effectiveness hypothesis will evaluate carbon monoxide (co) verified, six-month, seven-day point prevalence cessation. process hypotheses will evaluate self-efficacy, quitline, and nrt use and test our hypothesized model that specific measured processes will partially mediate observed intervention effectiveness. using qualitative interviews with key stakeholders and plwh smokers, aim 3 will support nationwide m2q2-hiv dissemination assessing acceptability and contextual factors guided by the practical, robust implementation and sustainability model (prism). this project builds upon a long-standing, successful collaboration between institutions in vietnam (ministry of health, bach mai quitline, institute of population health and development, hanoi medical university) and umass chan medical school. the study team has expertise in smoking cessation, hiv intervention, including stigma related to concomitant substance use, and implementation of complex interventions. if proven effective, the vietnam ministry of health is committed to incorporating m2q2-hiv as a permanent part of the national infrastructure.

Eligibility criteria:
inclusion criteria: 1. diagnosed hiv infection (prevalent and incident hiv). 2. at least 18 years old. 3. current smoker. 4. be able to receive texts and read text (literate). exclusion criteria: 1. pregnant or planning to become pregnant during the next six months. 2. unable or unwilling to provide informed consent. 3. prior diagnosis of serious mental health illness. 4. smoker who helped develop the motivational texts used in the intervention (participated in aim 1). 5. family member of another participant in the study.

Keywords: mhealth
obesity in children and adolescents: associated risks and early intervention

Conditions: Obesity

Summary: the investigators hypothesize that metformin decreases weight, normalizes lipid profile and increases insulin sensitivity; the study team hope to get better effect of weight decrease and metabolic processes repair in the intensive treatment group with intervention of physical activity, diet correction and metformin use.

during the first visit, study participants would follow the clinical investigation (anthropometry, physical examination, blood tests (hormonal and biochemical state), bioimpedance, ultrasound evaluation) and be attributed into 4 groups (matched for age, gender, pubertal stage and bmi), 100 subjects in each group. 1. st group - control: during the first visit patients get standardized information on healthy lifestyle, diet and exercise. next visit (control) will be scheduled for the clinical and laboratory evaluation after 12 months of intervention. 2. nd group - intensive diet and physical activity group: children will be seen 1. by a dietician once a month for diet re-evaluation; 2. physical therapist, who will give physical activity course twice a week (1 h each). 3. pediatric endocrinologist every 3 months. clinical and laboratory evaluation after 12 months of intervention. 3. rd group - intensive diet and physical activity group plus insulin sensitization: metformin will be prescribed for this group of study children in the doses of 1000 mg/day children will be seen by 1. a dietician once a month for diet re-evaluation; 2. physical therapist, who will give physical activity course twice a week (1 h each); 3. pediatric endocrinologist every 3 month. clinical and laboratory evaluation after 12 months of intervention. 4. th group- insulin sensitization without intensive diet and physical activity. metformin will be prescribed in the doses of 1000 mg/day after standardized information on healthy lifestyle, diet and exercise during the first visit only. this group of children will be seen by pediatric endocrinologist every 3 months. intervention duration - 12 months. in the case of metformin intolerance, children will continue the study in 2nd group. clinical and laboratory evaluation after 12 months of intervention.

Eligibility criteria:
inclusion criteria: * age 10-17 yrs; * weight \> 85th percentile for age and gender (by iotf); * living in kaunas and its region; * no obvious chronic diseases; * not on steroid or other long-term treatment; * informed consent of the patient and parents (official caregivers); exclusion criteria: * age less than 10 or above 17 yrs; * diagnosis of type 1 diabetes; * chronic illness that may affect physical activity and metabolic profile; * insulin treatment; * steroid treatment; * planning to move from kaunas or its region in the period of 1 year; * protocol refused by the patient or his parents;

Keywords: weight body mass index lipid profile glucose profile
safety and efficacy study of r932348 ophthalmic solution in chronic ocular graft versus host disease patients(drops-2)

Conditions: Chronic Graft-versus-host Disease

Summary: * to assess the efficacy of r348 ophthalmic solutions administered for 12 weeks to subjects evaluated by objective and subjective measures. * to investigate the safety and tolerability of r348 ophthalmic solutions administered for 12 weeks to subjects.


Eligibility criteria:
inclusion criteria: * received an allogeneic hematologic stem cell transplantation at least 3 months prior. * subjects with post allogeneic hematologic stem cell transplantation onset or worsening of dry eye symptoms for at least 1 month prior. * use of over-the-counter and/or prescription eye drops for dry eye symptoms within 1 month. * corneal fluorescein staining score of ≥ 2 in 1 region and ≥ 1 in at least 1 other region. * total lissamine green conjunctival staining score (according to a modified national eye institute grading system) of ≥ 2. exclusion criteria: * clinically unstable graft versus host disease (requiring a change in immunosuppressive regimen), medical condition, or laboratory abnormality * used topical ophthalmic cyclosporine within 45 days. * used any topical ophthalmic steroid within 2 weeks. * used autologous serum eye drops within 2 weeks.

Keywords: chronic graft versus host disease keratoconjunctivitis sicca
verticality perception in stroke patients

Conditions: Verticality Perception in Stroke

Summary: the long-term goal of this research is to advance our knowledge of how information from the labyrinth is brought to perception and how adaptation to vestibular imbalance influences spatial orientation. in healthy human subjects verticality perception is accurate while upright.the strategy of this research is to quantify changes in verticality perception after unilateral lesions along the central graviceptive pathways and to assess the frequency and pattern of abnormal verticality perception in patients with acute stroke (ischemic or hemorrhagic). our underlying hypothesis is that screening for erroneous verticality perception by use of a mobile device assessing the subjective visual vertical (svv) during the acute phase (i.e., within 24-48 hours after symptom onset) reliably identifies those patients with defects. early detection of deficits in verticality perception may help to initiate balance physiotherapy early.


Eligibility criteria:
inclusion criteria: 1. ages 18-90 years 2. informed consent 3. for group 1: acute (i.e. symptom onset \<3 days ago) lateralized ischemia or hemorrhage as confirmed by clinical examination and / or brain imaging (ct or mri). 4. absence of exclusion criteria exclusion criteria: 1. history of a peripheral-vestibular deficit 2. disturbed consciousness 3. severe sensory or motor aphasia 4. visual field deficits 5. other neurological or systemic disorder which can cause dementia or cognitive dysfunction 6. intake of antidepressants, sedatives, or neuroleptics
effects of cervical distraction versus cervical traction techniques on upper cervical pain

Conditions: Neck Pain

Summary: the aim of this study is to compare the effects of cervical distraction versus cervical traction techniques on pain, range of motion and function in patients with upper cervical pain. this study will be randomized clinical trial and 42 patients according to inclusion criteria will be included in the study. they will be allocated into 2 groups by non-probability purposive sampling technique. group a will receive cervical distraction technique with conventional physical therapy while group b will receive cervical traction technique with conventional therapy. outcome measures; neck disability index, goniometry and numeric pain rating scale will measure neck function and neck pain intensity. both groups will receive 5 sessions per week for 4 weeks and measurements will be taken at the baseline and at the end of 4th week. data will be analyzed by spss version 25

the term collectively used for musculoskeletal conditions originating from cervical area is known as neck pain. according to the global burden of disease (2010) study, neck pain is the fourth agent which is the reason behind chronic disability. the incidence of cervical pain in the adult population aged 15 to 74 years is 5.92% to 38.7% and it is more prevalent in women than men. the best predictor of future neck pain is the presence of an episode of neck pain in the past. cervical rotation deficits are noted mostly in upper cervical spine issues as in atlantoaxial joint pathology. the aim of this study is to compare the effects of cervical distraction versus cervical traction techniques on pain, range of motion and function in patients with upper cervical pain. this study will be a randomized clinical trial and 42 patients according to inclusion criteria will be included in the study. they will be allocated into 2 groups by non-probability purposive sampling technique. group a will receive the cervical distraction technique with conventional physical therapy while group b will receive the cervical traction technique with conventional therapy. outcome measures; neck disability index, goniometry and numeric pain rating scale will measure neck function and neck pain intensity. both groups will receive 5 sessions per week for 4 weeks and measurements will be taken at the baseline and at the end of 4th week. data will be analyzed by spss version 25.

Eligibility criteria:
inclusion criteria: * minimum 3 months chronicity of upper cervical pain * positive ﬂexion-rotation test (asymmetry of \>10◦ between sides or less than 32◦ in any direction) * hypomobility in one or more segments of c0-1, c1-2, or c2-3 exclusion criteria: * congenital abnormalities (cervical torticollis) * past surgical history of cervical spine * any history of neck trauma * already undergone physiotherapy treatment

Keywords: cervical pain traction distraction
to assess the safety, tolerability, pharmacokinetics and pharmakodynamics of azd2820 after multiple ascending doses

Conditions: Obesity

Summary: this is a randomised and single-blind, placebo-controlled study to investigate the safety, tolerabilty, pharmacokinetics and pharmacodynamics of repeated and ascending doses of azd2820 to obese but otherwise healthy male subjects.

a phase i, single centre, single-blind, randomised, placebo-controlled, parallel-group study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of azd2820 after administration of multiple ascending doses.

Eligibility criteria:
inclusion criteria: * provision of signed and dated, written informed consent prior to any study specific procedures including the genetic sampling and analyses * obese but otherwise healthy male subjects aged 18 - 45 years with suitable veins for cannulation or repeated venepuncture * male subjects should be willing to use barrier contraception ie, condoms, from the first day of dosing until 3 months after the last dose of investigational product * have a body mass index (bmi) between 27 and 40 kg/m2 exclusion criteria: * history of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the stud * a history of erectile dysfunction or anatomic abnormality of the penis (eg, cavernosal fibrosis, peyronie's disease, or plaques) which interferes with normal erectile function * prolonged qtcf \>450 ms or shortened qtcf \<340 ms or family history of long qt syndrome * history of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to azd2820 * any clinically significant abnormalities in clinical chemistry, haematology (including eosinophilia) or urinalysis results as judged by the investigator

Keywords: phase 1 obese healthy male volunteers multiple doses dose escalation pharmacokinetics pharmakodynamics
supporting decision making for musculoskeletal preference-sensitive care

Conditions: Knee Pain Chronic; Arthritis (Hip); Arthritis (Knee); Back Pain

Summary: the purpose of this study is to compare condition oriented whole person health coaching along with the provision of decision aids to decision aids without condition oriented health coaching to neither condition oriented health coaching nor decision aids on medical cost, preference sensitive surgeries and measures of subject knowledge, decision process and decision quality.


Eligibility criteria:
inclusion criteria: * participants in two large, commercial blue cross and/or blue shield branded insurance products with eligibility for health dialog services * identified by distinct health dialog proprietary models for risk of lumbar back, knee or hip surgeries * selected by simple randomization for inclusion in an interactive voice response (ivr) administered screening survey * participated in an ivr-administered screener survey and responded affirmatively to questions on pain for any one of the three conditions, any current or planned treatment for the conditions, and responded negatively to having had a condition specific surgery within the past six months exclusion criteria: * people under 18 years of age at time of identification for the ivr filtering survey, approximately 6 weeks prior to the start of the study * people with invalid phone numbers or invalid mailing addresses based on automated review of those fields * people for whom health dialog has information of a request for no ivr, no health coach outreach, or mailings prior to the start of the study * people with claims based indication of spinal stenosis prior to the start of the study * people who have been targeted for any ivr outreach within 180 days of the initiation of the ivr filtering survey * people who have a health coach communication record, as documented in the health coaching application within 90 days of the start of the study * any members of households who have a household member already selected for inclusion in the study * people for whom there is claims evidence of any one of the targeted surgeries prior the start of the study * people with no eligibility for services through insurer after the start of the study
the effect of gabapentin, ketamine and dexamethasone on pain and opioid requirements after hip surgery

Conditions: Pain, Postoperative

Summary: patients scheduled for primary hip replacement needs postoperative pain treatment, i.e. morphine. morphine has side-effects: nausea, vomiting, sedation and dizziness. these side-effects are unpleasant for the patients and sometimes keeps them at bed longer time than needed. we investigate in new combinations of analgesics for postoperative pain, hoping to minimize the need for morphine.

the effect on postoperative pain of the combination of preoperative gabapentin 1200 mg + dexamethasone 8 mg + ketamine 0.15mg/kg versus placebo is investigated on patients having a hip alloplastic operation.

Eligibility criteria:
inclusion criteria: * patients scheduled for primary total hip replacement, * between 55 and 85 years of age, * asa 1-3 and bmi between 18 and 35. exclusion criteria: patients who are: * unable to cooperate * does not speak danish * has allergy for drugs used in the trial * drug or alcohol abuse * epilepsy * medically treated diabetes * known kidney disease * daily use of analgetics * apart from nsaid * paracetamol or cox2 inhibitors * are treated with a antidepressive.

Keywords: primary hip replacement gabapentin dexamethasone ketamine multimodal postoperative analgesia.
a phase 1 study of shr-a1811 in patients with selected her2 expressing tumors

Conditions: Gastric Cancer; Colorectal Cancer

Summary: this is a single arm, open-label, dose escalation, pk expansion and efficacy expansion study of phase i. the purpose of this study is to assess the tolerability, safety, pharmacokinetics and immunogenicity of shr-a1811 and preliminary anti-tumor efficacy in her2-expressing advanced gastric or gastroesophageal junction adenocarcinoma and colorectal cancer.


Eligibility criteria:
inclusion criteria: * has a pathologically or cytologically documented advanced/unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma and colorectal cancer that is refractory to or intolerable with standard treatment, or for which no standard treatment is available. * at least one evaluable or measurable lesion should be present and identified according to response evaluation criteria in solid tumors(recist) version 1.1. * has an ecog ps 0-1. * has a life expectancy of ≥ 3 months. * has adequate organ function exclusion criteria: * has unresolved toxicities from previous anticancer therapy, defined as toxicities not yet resolved to nci-ctcae version 5.0 grade ≤ 1. * has received her2 antibody drug conjugates,. * central nervous system metastasis or meningeal metastasis with clinical symptoms * has active infection requiring systemic treatment.